Filing Analysis
Securities Offering
Filed Apr 28, 2026
LOW
Adicet Bio entered into an exchange agreement with RA Capital to swap 250,000 shares of common stock for a pre-funded warrant for an equivalent number of shares. This transaction allows the institutional investor to manage beneficial ownership thresholds while maintaining its economic exposure to the company.
Key Facts
- On April 27, 2026, the Company exchanged 250,000 shares of common stock for a pre-funded warrant with RA Capital.
- The pre-funded warrant allows for the purchase of 250,000 shares at a nominal exercise price of $0.0001 per share.
- The warrant includes a beneficial ownership blocker of 9.99%, which can be increased to 19.99% upon 61 days' notice.
- The transaction was conducted as an unregistered exchange under Section 3(a)(9) of the Securities Act of 1933.
- The exchange is non-dilutive relative to the total shares and equivalents already held by the investor.
Regulation FD Disclosure
Filed Mar 12, 2026
LOW
Adicet Bio, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished as an exhibit to the filing.
Key Facts
- Reported financial results for the quarter and year ended December 31, 2025
- Filing date: March 12, 2026
- Information furnished under Item 2.02 (Results of Operations and Financial Condition)
- Exhibit 99.1 contains the full press release
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.